文献速递甲状腺疾病

视网膜母细胞瘤蛋白表达降低与甲状腺髓样癌患者生存期缩短相关

Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.
PubMed 文献 · Thyroid · 2017-01-01

本研究对56例甲状腺髓样癌(MTC)患者的74份样本(51份原发肿瘤、23份淋巴结转移灶)行免疫组化检测RB与磷酸化RB(pRB)表达,并由两位病理专家盲法判读。

要点

  • 原发肿瘤RB核表达弥漫阳性者占88%,淋巴结转移灶占78%。
  • 原发肿瘤与淋巴结转移灶中pRB核表达阳性者均占22%。
  • 原发肿瘤RB低表达在多因素分析中与更差疾病特异性及总生存独立相关。

核心结论

  • RB表达降低在单因素和多因素分析中均与患者生存期缩短相关,且独立于手术时年龄或晚期TNM分期。
  • 作者认为需要更大样本的MTC患者研究来确定较低RB表达水平是否可作为侵袭性疾病的生物标志物。

研究设计与样本

  • 对MTC患者的福尔马林固定石蜡包埋原发甲状腺肿瘤和淋巴结转移灶行降钙素、RB及磷酸化RB(pRB)免疫组化检测。
  • 两位病理专家盲法判读切片,并将免疫组化结果与疾病特异性生存(主要终点)比较。
  • 共分析来自56例患者的74份MTC样本,包括51份原发肿瘤和23份淋巴结转移灶。

主要发现

  • 中位随访时间为术后6.75年(范围0.64-24.30年),原发肿瘤中位大小为30 mm(范围6-96 mm)。
  • 66%的病例被分类为IV期。
  • RB核表达在原发肿瘤中弥漫存在者占88%,在淋巴结转移灶中占78%;pRB核表达在原发肿瘤中占22%,在淋巴结转移灶中占22%。
  • 原发肿瘤多因素分析显示,RB核低表达与更差的疾病特异性生存(p=0.01)和总生存(p=0.02)独立相关;pRB水平与原发肿瘤或淋巴结转移灶的生存均无关联。

局限性

  • 作者认为需要更大样本的MTC患者研究来确定较低RB表达水平是否可作为侵袭性疾病的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The retinoblastoma (RB) transcriptional corepressor 1 protein functions to slow cell-cycle progression. Inactivation of RB by reduced expression and/or hyperphosphorylation allow for enhanced progression through the cell cycle. Murine models develop medullary thyroid carcinoma (MTC) after generalized loss of RB. However, RB expression in MTC has only been evaluated in a small number of tumors, with differing results. The objective of this study was to determine whether reduced expression of RB and/or overexpression of hyperphosphorylated RB predict MTC aggressive behavior. METHODS: Formalin-fixed, paraffin-embedded primary thyroid tumors and lymph node metastases from MTC patients were evaluated for calcitonin, RB, and phosphorylated RB (pRB) expression by immunohistochemistry. Two expert pathologists evaluated the slides in a blinded manner, and the immunohistochemistry results were compared to disease-specific survival as a primary endpoint. RESULTS: Seventy-four MTC samples from 56 patients were analyzed in this study, including 51 primary tumors and 23 lymph node metastases. The median follow-up time was 6.75 years after surgery (range 0.64-24.30 years), and the median primary tumor size was 30 mm (range 6-96 mm). Sixty-six percent of cases were classified as stage IV. RB nuclear expression was diffusely present in 88% of primary tumors and 78% of lymph node metastases. Nuclear pRB expression was present in 22% of primary tumors and 22% of lymph node metastases. On univariate analysis, reduced RB (<75% tumor cell staining) trended with lower MTC-specific survival for primary tumor and metastatic nodes (primary tumor hazard ratio = 3.54 [confidence interval 0.81-15.47], p = 0.08; and lymph node hazard ratio = 4.35 [confidence interval 0.87-21.83], p = 0.05). For primary tumors, multivariable analysis showed that low nuclear RB expression was independently associated with worse disease-specific (p = 0.01) and overall (p = 0.02) survival. pRB levels were not associated with survival for either primary tumor or lymph node metastases. CONCLUSIONS: Reduced RB expression is associated with decreased patient survival in univariate and multivariable analyses, independent from patient age at surgery or advanced TNM stage. Future studies involving larger MTC patient populations are warranted to determine if lower RB expression levels may serve as a biomarker for aggressive disease in patients with MTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Valenciaga A, Grubbs EG, Porter K, et al. Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer. Thyroid. 2017. PMID: 29105562. doi:10.1089/thy.2017.0113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。